Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Super-Affinity Antibody

InVivoMAb Anti-Mouse CTLA4 & OX40 Bispecific Antibody (Iv0227)

Catalog #:   VMD17204 Specific References (50) DATASHEET
Host species: Mouse
Isotype: IgG
Applications: FuncS
Accession: P09793 & P47741
Overview

Catalog No.

VMD17204

Species reactivity

Mouse

Host species

Mouse

Isotype

IgG

Clonality

Monoclonal

Target

Bispecific, Cytotoxic T-lymphocyte protein 4, Cytotoxic T-lymphocyte-associated antigen 4, CTLA-4, CD152, Ctla4, Cd152, Tumor necrosis factor receptor superfamily member 4, OX40 antigen, OX40L receptor, CD134, Tnfrsf4, Ox40, Txgp1

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P09793 & P47741

Applications

FuncS

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

Iv0227

Data Image
References

Immune checkpoint inhibitors in cancer therapy: what lies beyond monoclonal antibodies?, PMID:40536609

Cancer cells accelerate exhaustion of persistently activated mouse CD4+ T cells., PMID:40536473

Palmitoylation-driven immune dysregulation and prognostic signature in low-grade glioma: a multi-omics and functional validation study., PMID:40535771

F-box proteins at the crossroads of ubiquitination and tumor immunity: regulatory networks and immunotherapy strategies., PMID:40534867

Immunolocalization of CD28, CTLA-4 and CD80 in Non-Small Cell Lung Carcinoma: Combined CD28/CTLA-4/CD80 Status is a Potent Prognostic Factor of These Patients., PMID:40533179

Risk of pituitary immune-related adverse events caused by immune checkpoint inhibitors:a systematic review and meta-analysis., PMID:40532761

Tumor-Associated Glycan Exploits Adenosine Receptor 2A Signaling to Facilitate Immune Evasion., PMID:40532063

An evaluation of Nivolumab and ipilimumab for the treatment of resectable stage III melanoma., PMID:40531544

Identification of CENPW as a prognostic biomarker and potential therapeutic target for clear cell renal cell carcinoma., PMID:40531390

Seven Hypoxia and Immune-Related Features Predict Prognosis in Patients with Hepatocellular Carcinoma., PMID:40531258

The comparison of efficacy and safety between cadonilimab (PD-1/CTLA-4) and anti-PD-1 inhibitors in patients with recurrent or metastatic cervical cancer: a retrospective real-world study., PMID:40529375

The next generation of immunotherapies for lung cancers., PMID:40528044

Spatial Transcriptomic Landscape of Canine Oral Squamous Cell Carcinoma., PMID:40525754

Systematic Pan-Cancer Analysis of the Oncogenic and Immunological Function of Stanniocalcin-1 (STC1)., PMID:40525442

Radiation-Based Multi-Modal Therapy Combining with Immunotherapy to Develop a Vaccine-Like Effective Treatment for Triple-Negative Breast Cancer., PMID:40524764

High tumor expression of CTLA4 identifies lymph node-negative basal-like breast cancer patients with excellent prognosis., PMID:40523912

Efficacy and safety of HBM4003 combined with toripalimab in refractory neuroendocrine neoplasms: a multicenter, phase II study., PMID:40521168

Blockade of colon cancer metastasis via single and double silencing of PCSK7/PCSK9: enhanced T cells cytotoxicity in mouse and human., PMID:40518289

T cell-mediated mechanisms of immune-related adverse events induced by immune checkpoint inhibitors., PMID:40517973

Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Relapsed or Refractory Lymphoma., PMID:40514309

Advanced biomaterials for the targeted delivery of immune checkpoint inhibitors to solid tumors., PMID:40513669

Emerging Immunotherapy Targets in Early Drug Development., PMID:40508202

Recent Advances in Molecular Research and Treatment for Melanoma in Asian Populations., PMID:40508177

Impaired Overall Survival of Melanoma Patients Due to Antibiotic Use Prior to Immune Checkpoint Inhibitor Therapy: Systematic Review and Meta-Analysis., PMID:40507352

Immune Checkpoint Inhibitors in the Treatment of Advanced Melanoma in Older Patients: An Overview of Published Data., PMID:40507314

Advances in drug treatments for male patients with prolactinomas., PMID:40505642

Association between CTLA4-658C>T Polymorphism and Colorectal Cancer in Medan, Indonesia., PMID:40504777

High antigen burden drives CD8+ T cell dysfunction in a mouse model of chronic hepatitis B virus infection., PMID:40503880

PD-1 is conserved from sharks to humans: new insights into PD-1, PD-L1, PD-L2, and SHP-2 evolution., PMID:40503235

NEXUS: a phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies., PMID:40502306

SGSM1 as a pan-cancer biomarker: multi-omics insights into immune regulation, prognostic value, and therapeutic implications., PMID:40500484

Uncovering PD-L1 among immune cell predictive biomarkers and actionable genetic alterations in anal squamous-cell carcinomas in the era of immunotherapy., PMID:40499464

Role of Ischemia/Reperfusion and Oxidative Stress in Shock State., PMID:40497985

The dual role of TIGIT in regulatory and effector T cells in chronic liver disease., PMID:40496440

Tumor clusters with divergent inflammation and human retroelement expression determine the clinical outcome of patients with serous ovarian cancer., PMID:40492347

Harnessing the Power of Chlorogenic Acid: Inhibiting IL-2-Mediated Treg Upregulation to Combat Post-Traumatic Osteomyelitis., PMID:40485518

Pregnancy-associated thyroid disorders: the role of genetic, epigenetic, and oxidative stress factors., PMID:40484893

Serum PD-L1 and CTLA-4 levels as biomarkers of acute rejection and renal dysfunction in kidney transplant recipients., PMID:40482974

Dual blockade of PD-1 and CTLA-4 generates long-lasting immunity against irradiated glioblastoma., PMID:40482909

CTLA-4 blockade in ovarian cancer immunotherapy: Mechanisms and clinical strategies., PMID:40482550

Immunohistochemical expression of PD1, LAG3, and CTLA4 in diffuse large B cell lymphoma, clinicopathological correlation, and prognostic value., PMID:40481915

The immunosurveillance signature predicts the prognosis and immunotherapy sensitivity for colon adenocarcinoma., PMID:40481062

Targeting B and T lymphocyte attenuator in cancer immunotherapy., PMID:40480574

Co-regulation of miRNA and lncRNA on immunosuppression gene: unveiling the regulatory networks in cancer., PMID:40479646

Adding immune checkpoint inhibitors to chemotherapy in elderly cancer patients: Beneficial for many but not all?, PMID:40476645

Comprehensive evaluation of clinical phenotypes and pathogenic features in late-onset monogenic inflammatory bowel disease: a comparative study with infantile-onset cases., PMID:40474095

Characterisation of an autochthonous mouse ccRCC model of immune checkpoint inhibitor therapy resistance., PMID:40473819

Unveiling alternative splicing dynamics in activated T lymphocytes and their implications for immune checkpoint blockade efficacy., PMID:40469104

CTLA4 Single-Nucleotide Polymorphisms Influence the Risk of HSV and VZV Infection in Kidney Transplant Recipients: A Prospective Cohort Study., PMID:40469083

Immune-mediated enterocolitis is associated with immune checkpoint inhibitors: A pharmacovigilance study from the FDA Adverse Event Reporting System (FAERS) database., PMID:40465755

Datasheet
$ 484
Product specifications
100 μg 484 1 mg 1932

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

InVivoMAb Anti-Mouse CTLA4 & OX40 Bispecific Antibody (Iv0227) [VMD17204]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only